Late relapse of testicular cancer

J. Baniel, Richard Foster, R. Gonin, J. E. Messemer, J. P. Donohue, Lawrence Einhorn

Research output: Contribution to journalArticle

263 Citations (Scopus)

Abstract

Purpose: This study analyzed a large group of patients with testicular germ cell cancer in complete remission, who relapsed more than 2 years after completion of treatment. Patients and Methods: A review of all patients treated at Indiana University Medical Center from 1979 through 1992 for late relapse was conducted. Eighty-one patients were treated for late relapse of testicular cancer. Forty-seven patients relapsed more than 5 years after successful management of their initial disease. Results: At initial diagnosis, 35 patients had clinical stage I, 18 stage II, and 28 stage III disease. Twenty-three of 35 stage I, all 18 stage II, and all 28 stage III patients were treated by chemotherapy before their late relapse. The median follow-up duration of patients post-management of late relapse was 4.8 years. Twenty-one patients (25.9%) are continuously disease-free. Nineteen of these 21 patients had surgical resection of carcinoma or teratoma as a component of their therapy. Of sixty-five patients treated for late relapse by chemotherapy, 17 (26.2%) had a complete response, but only two have been continuously disease-free with chemotherapy alone. These two never received prior chemotherapy. Conclusion: Late relapse of testis cancer is more common than previously thought. Surgery is the preferred mode of therapy. Chemotherapy has only modest success in this entity, in contrast to the excellent results in de novo germ cell tumors. Patients treated for testicular germ cell cancer need annual follow-up evaluations throughout their life due to the possibility of late relapse.

Original languageEnglish
Pages (from-to)1170-1176
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number5
StatePublished - 1995

Fingerprint

Testicular Neoplasms
Recurrence
Germ Cell and Embryonal Neoplasms
Drug Therapy
Teratoma
Therapeutics
Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Baniel, J., Foster, R., Gonin, R., Messemer, J. E., Donohue, J. P., & Einhorn, L. (1995). Late relapse of testicular cancer. Journal of Clinical Oncology, 13(5), 1170-1176.

Late relapse of testicular cancer. / Baniel, J.; Foster, Richard; Gonin, R.; Messemer, J. E.; Donohue, J. P.; Einhorn, Lawrence.

In: Journal of Clinical Oncology, Vol. 13, No. 5, 1995, p. 1170-1176.

Research output: Contribution to journalArticle

Baniel, J, Foster, R, Gonin, R, Messemer, JE, Donohue, JP & Einhorn, L 1995, 'Late relapse of testicular cancer', Journal of Clinical Oncology, vol. 13, no. 5, pp. 1170-1176.
Baniel J, Foster R, Gonin R, Messemer JE, Donohue JP, Einhorn L. Late relapse of testicular cancer. Journal of Clinical Oncology. 1995;13(5):1170-1176.
Baniel, J. ; Foster, Richard ; Gonin, R. ; Messemer, J. E. ; Donohue, J. P. ; Einhorn, Lawrence. / Late relapse of testicular cancer. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 5. pp. 1170-1176.
@article{56655a775b2f4f12a706e8ba001162aa,
title = "Late relapse of testicular cancer",
abstract = "Purpose: This study analyzed a large group of patients with testicular germ cell cancer in complete remission, who relapsed more than 2 years after completion of treatment. Patients and Methods: A review of all patients treated at Indiana University Medical Center from 1979 through 1992 for late relapse was conducted. Eighty-one patients were treated for late relapse of testicular cancer. Forty-seven patients relapsed more than 5 years after successful management of their initial disease. Results: At initial diagnosis, 35 patients had clinical stage I, 18 stage II, and 28 stage III disease. Twenty-three of 35 stage I, all 18 stage II, and all 28 stage III patients were treated by chemotherapy before their late relapse. The median follow-up duration of patients post-management of late relapse was 4.8 years. Twenty-one patients (25.9{\%}) are continuously disease-free. Nineteen of these 21 patients had surgical resection of carcinoma or teratoma as a component of their therapy. Of sixty-five patients treated for late relapse by chemotherapy, 17 (26.2{\%}) had a complete response, but only two have been continuously disease-free with chemotherapy alone. These two never received prior chemotherapy. Conclusion: Late relapse of testis cancer is more common than previously thought. Surgery is the preferred mode of therapy. Chemotherapy has only modest success in this entity, in contrast to the excellent results in de novo germ cell tumors. Patients treated for testicular germ cell cancer need annual follow-up evaluations throughout their life due to the possibility of late relapse.",
author = "J. Baniel and Richard Foster and R. Gonin and Messemer, {J. E.} and Donohue, {J. P.} and Lawrence Einhorn",
year = "1995",
language = "English",
volume = "13",
pages = "1170--1176",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Late relapse of testicular cancer

AU - Baniel, J.

AU - Foster, Richard

AU - Gonin, R.

AU - Messemer, J. E.

AU - Donohue, J. P.

AU - Einhorn, Lawrence

PY - 1995

Y1 - 1995

N2 - Purpose: This study analyzed a large group of patients with testicular germ cell cancer in complete remission, who relapsed more than 2 years after completion of treatment. Patients and Methods: A review of all patients treated at Indiana University Medical Center from 1979 through 1992 for late relapse was conducted. Eighty-one patients were treated for late relapse of testicular cancer. Forty-seven patients relapsed more than 5 years after successful management of their initial disease. Results: At initial diagnosis, 35 patients had clinical stage I, 18 stage II, and 28 stage III disease. Twenty-three of 35 stage I, all 18 stage II, and all 28 stage III patients were treated by chemotherapy before their late relapse. The median follow-up duration of patients post-management of late relapse was 4.8 years. Twenty-one patients (25.9%) are continuously disease-free. Nineteen of these 21 patients had surgical resection of carcinoma or teratoma as a component of their therapy. Of sixty-five patients treated for late relapse by chemotherapy, 17 (26.2%) had a complete response, but only two have been continuously disease-free with chemotherapy alone. These two never received prior chemotherapy. Conclusion: Late relapse of testis cancer is more common than previously thought. Surgery is the preferred mode of therapy. Chemotherapy has only modest success in this entity, in contrast to the excellent results in de novo germ cell tumors. Patients treated for testicular germ cell cancer need annual follow-up evaluations throughout their life due to the possibility of late relapse.

AB - Purpose: This study analyzed a large group of patients with testicular germ cell cancer in complete remission, who relapsed more than 2 years after completion of treatment. Patients and Methods: A review of all patients treated at Indiana University Medical Center from 1979 through 1992 for late relapse was conducted. Eighty-one patients were treated for late relapse of testicular cancer. Forty-seven patients relapsed more than 5 years after successful management of their initial disease. Results: At initial diagnosis, 35 patients had clinical stage I, 18 stage II, and 28 stage III disease. Twenty-three of 35 stage I, all 18 stage II, and all 28 stage III patients were treated by chemotherapy before their late relapse. The median follow-up duration of patients post-management of late relapse was 4.8 years. Twenty-one patients (25.9%) are continuously disease-free. Nineteen of these 21 patients had surgical resection of carcinoma or teratoma as a component of their therapy. Of sixty-five patients treated for late relapse by chemotherapy, 17 (26.2%) had a complete response, but only two have been continuously disease-free with chemotherapy alone. These two never received prior chemotherapy. Conclusion: Late relapse of testis cancer is more common than previously thought. Surgery is the preferred mode of therapy. Chemotherapy has only modest success in this entity, in contrast to the excellent results in de novo germ cell tumors. Patients treated for testicular germ cell cancer need annual follow-up evaluations throughout their life due to the possibility of late relapse.

UR - http://www.scopus.com/inward/record.url?scp=0029003920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029003920&partnerID=8YFLogxK

M3 - Article

C2 - 7537800

AN - SCOPUS:0029003920

VL - 13

SP - 1170

EP - 1176

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -